CCCC C4 Therapeutics (CCCC) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001662579
Form 144 · 4
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
105
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $2.3K priced
What the filings say about CCCC
Planned sales (Form 144), 90 days
$2.1M
4 notices
C4 Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for C4 Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 6.4% of the 156,382 shares held after it.
- No other insider sold within 30 days.
- 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer REYNO LEONARD sold about $22.2K of CCCC on Jan 16, 2026, the largest insider sale at the company since 2022; 105 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 14, 2025.
- The trade is 0.6% of the 107,805 shares held after it.
- No other insider sold within 30 days.
- 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Business Officer Boyle Scott N sold about $2.1K of CCCC on Feb 18, 2025, the largest insider sale at the company since 2022; 105 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.4% of the 110,842 shares held after it.
- No other insider sold within 30 days.
- 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Business Officer Boyle Scott N sold about $1.5K of CCCC on Feb 14, 2025, the largest insider sale at the company since 2022; 105 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 5,667 shares held after it.
- No other insider bought within 30 days.
- 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Koppikar Utpal bought about $31.7K of CCCC on Feb 8, 2023; 105 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 10,000 shares held after it.
- No other insider bought within 30 days.
- 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Hirsch Andrew bought about $84.0K of CCCC on Apr 12, 2022, the largest insider purchase at the company on our record; 105 funds added in the latest 13F quarter.50 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
105 funds bought in last quarter
more than 71% of Pharma & Biotech
Revenue
+1.0% year over year
below 51% of Pharma & Biotech
Margin
-292.1% net margin
below 71% of Pharma & Biotech
Buybacks
$200.0K repurchased, FY to 2026-06-30
below 94% of Pharma & Biotech
Short interest
42.8% of the float short (float per yahoo 2026-10-26) · 17.6 days to cover · settled 2026-09-30
the highest in Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CCCC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+34.9%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CCCC: institutional holders (13F)
13F holdings, latest reported quarter
14,653,382 sh
$68.4M
8,867,338 sh
$41.4M
8,000,000 sh
$37.4M
7,896,718 sh
$36.9M
7,200,000 sh
$33.6M
Congress trades in CCCC
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CCCC planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
JAY GELDMACHER
Filed 2026-08-14
$1.9M
Mark Mossler
Filed 2026-08-14
$17.6K
Mark Mossler
Filed 2026-08-13
$61.1K
Mark Mossler
Filed 2026-08-12
$76.7K
CCCC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Wasatch Ultra Growth Fund
$11.7M position · as of 2026-06-30
2.5%
Wasatch Long/Short Alpha Fund
$852.6K position · as of 2026-06-30
2.2%
Invesco NASDAQ Future Gen 200 ETF
$124.4K position · as of 2026-05-31
0.7%
Wasatch Micro Cap Fund
$3.6M position · as of 2026-06-30
0.5%
Ultra-Small Company Market Fund
$560.4K position · as of 2026-06-30
0.4%
Small Cap Value Fund
$1.4M position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
4
Phase 1
2 active
1
Phase 2
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Mr. Hirsch
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.9M
$1.3M
$1.6M
-68%
n/a
2024
$4.6M
$905.0K
$2.3M
-39%
n/a
2023
$3.8M
$4.3M
$1.6M
-4%
n/a
2022
$2.6M
-$21.6M
$3.5M
-82%
n/a
2021
$952.2K
-$79.7K
$3.9M
-3%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows 105 funds added last quarter, $2.1M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
CCCC financials
Revenue growth
+1.0%
XBRL, annual
Net margin
-292.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$35.0M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CCCC
| FY Dec 2025 | $35.9M |
| FY Dec 2024 | $35.6M |
| FY Dec 2023 | $20.8M |
| FY Dec 2022 | $31.1M |
| FY Dec 2021 | n/a |
| Jun 2026 | $6.6M |
| Mar 2026 | $6.2M |
| Dec 2025 | $11.0M |
| Sep 2025 | $11.2M |
| Jun 2025 | $6.5M |
| Mar 2025 | $7.2M |
| Dec 2024 | $5.2M |
| Sep 2024 | $15.4M |
At each fiscal year end
Single quarter
Net margin, TTM
-289.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CCCC
| FY Dec 2025 | -292.1% |
| FY Dec 2024 | -296.0% |
| FY Dec 2023 | -638.3% |
| FY Dec 2022 | -412.2% |
| FY Dec 2021 | n/a |
| Jun 2026 | -355.9% |
| Mar 2026 | -408.5% |
| Dec 2025 | -186.0% |
| Sep 2025 | -286.4% |
| Jun 2025 | -402.6% |
| Mar 2025 | -363.7% |
| Dec 2024 | -667.8% |
| Sep 2024 | -160.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$85.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CCCC
| FY Dec 2025 | -$99.3M |
| FY Dec 2024 | -$65.3M |
| FY Dec 2023 | -$108.5M |
| FY Dec 2022 | -$111.4M |
| FY Dec 2021 | -$88.2M |
| Jun 2026 | -$1.6M |
| Mar 2026 | -$30.0M |
| Dec 2025 | -$22.2M |
| Sep 2025 | -$31.6M |
| Jun 2025 | -$12.2M |
| Mar 2025 | -$33.3M |
| Dec 2024 | -$17.9M |
| Sep 2024 | -$24.1M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term 2023-12-31 (30 months older than the period end) plus current 2023-12-31 (30 months older than the period end); equity 2026-06-30
Debt to equity CCCC
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.04x |
| FY Dec 2021 | 0.03x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt CCCC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -9.23x |
| FY Dec 2021 | -8.08x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-48.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CCCC
| FY Dec 2025 | -44.4% |
| FY Dec 2024 | -45.6% |
| FY Dec 2023 | -49.5% |
| FY Dec 2022 | -37.8% |
| FY Dec 2021 | -25.0% |
| Jun 2026 | -48.1% |
| Mar 2026 | -48.3% |
| Dec 2025 | -44.4% |
| Sep 2025 | -60.0% |
| Jun 2025 | -53.0% |
| Mar 2025 | -45.6% |
| Dec 2024 | -45.6% |
| Sep 2024 | -46.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-30.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CCCC
| FY Dec 2025 | -29.6% |
| FY Dec 2024 | -29.0% |
| FY Dec 2023 | -32.8% |
| FY Dec 2022 | -27.3% |
| FY Dec 2021 | -18.5% |
| Jun 2026 | -30.9% |
| Mar 2026 | -32.0% |
| Dec 2025 | -29.6% |
| Sep 2025 | -37.1% |
| Jun 2025 | -32.9% |
| Mar 2025 | -28.8% |
| Dec 2024 | -29.0% |
| Sep 2024 | -29.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital CCCC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-39.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CCCC
| FY Dec 2025 | -36.6% |
| FY Dec 2024 | -37.5% |
| FY Dec 2023 | -38.6% |
| FY Dec 2022 | -30.8% |
| FY Dec 2021 | -20.2% |
| Jun 2026 | -39.7% |
| Mar 2026 | -39.2% |
| Dec 2025 | -36.6% |
| Sep 2025 | -46.2% |
| Jun 2025 | -42.7% |
| Mar 2025 | -37.5% |
| Dec 2024 | -37.5% |
| Sep 2024 | -37.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CCCC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$316.3M
market value at close 2026-10-27 on 2026-07-31 shares, plus long-term 2023-12-31 (30 months older than the period end) plus current 2023-12-31 (30 months older than the period end), minus cash 2026-06-30
Enterprise value CCCC
| FY Dec 2025 | $110.5M |
| FY Dec 2024 | $198.6M |
| FY Dec 2023 | $151.8M |
| FY Dec 2022 | $270.6M |
| FY Dec 2021 | $1.5B |
| Jun 2026 | $437.7M |
| Mar 2026 | $195.4M |
| Dec 2025 | $110.5M |
| Sep 2025 | $99.2M |
| Jun 2025 | $23.4M |
| Mar 2025 | $62.3M |
| Dec 2024 | $198.6M |
| Sep 2024 | $335.6M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-21.6%
TTM free cash flow over market value at close 2026-10-27
FCF yield CCCC
| FY Dec 2025 | -53.6% |
| FY Dec 2024 | -25.7% |
| FY Dec 2023 | -39.0% |
| FY Dec 2022 | -38.6% |
| FY Dec 2021 | -5.6% |
| Jun 2026 | -16.5% |
| Mar 2026 | -37.4% |
| Dec 2025 | -53.6% |
| Sep 2025 | -60.2% |
| Jun 2025 | -86.2% |
| Mar 2025 | -70.9% |
| Dec 2024 | -25.7% |
| Sep 2024 | -18.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CCCC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $35.9M | $35.6M | $20.8M | $31.1M |
| Operating income | -$115.2M | -$119.6M | -$139.0M | -$129.5M |
| Net income | -$105.0M | -$105.3M | -$132.5M | -$128.2M |
| EPS (diluted) | -1.27 | -1.52 | -2.67 | -2.62 |
| Operating cash flow | -$98.7M | -$65.2M | -$106.8M | -$105.9M |
| Cash | $74.6M | $55.5M | $126.6M | $29.8M |
| Long-term debt | n/a | n/a | $0 | $9.2M |
| Buybacks | $193.0K | $194.0K | $110.0K | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
CCCC Stock Sonar score 5/7 axes
Find similar shapesCompareCCCC ranks highest on financial health (99th percentile) and institutional and government (71st), and lowest on risk and compliance (10th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CCCC filings, in plain words
Are there planned insider sales of CCCC?
Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $2.1M of stock; the latest, by JAY GELDMACHER, was filed 2026-08-14.
Read the full summary
Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $2.1M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
